AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway.

NEW YORK, Oct. 7, 2026 /PRNewswire/ — Before the opening bell today, ArriVent BioPharma (NASDAQ: AVBP) shares were already down 56.7% in premarket trading after the Company disclosed that its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint. Shareholders holding AVBP at the time saw more than half of the stock’s value wiped out before regular trading began. Investors who suffered losses are encouraged to submit your AVBP loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.

Regular-session trading brought little relief. AVBP traded between 50% and 63% below its prior close and touched a 52-week low near $12.09. At least one report cited an intraday low of $11.88. The move was not tied to earnings or guidance. It followed a single program update on the FURVENT trial.

FURVENT studied firmonertinib, ArriVent’s lead pipeline candidate, in previously untreated patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer. Its primary endpoint was progression-free survival by blinded independent central review. The Company reported some secondary-endpoint benefits and no new safety signals, yet AVBP still traded at roughly half its prior-day value or less. SueWallSt has opened an investigation into potential securities law violations on behalf of affected AVBP investors.

If the October 6 sell-off cut into your AVBP holdings, request a review of your AVBP losses or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the AVBP Investigation

Q: How much did AVBP stock drop?A: Shares fell 56.7% in premarket trading and approximately 50% to 63% during the October 6, 2026 session, reaching a 52-week low near $12.09. The decline followed the Company’s disclosure that the Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether ArriVent BioPharma made materially false or misleading statements regarding the status and prospects of the Phase 3 FURVENT trial of firmonertinib. When the Company disclosed on October 6, 2026 that the trial did not meet its primary endpoint, the stock price declined sharply.

Q: When did ArriVent BioPharma allegedly mislead investors?A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What do AVBP investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my AVBP shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AVBP and sold at a loss may still participate in the investigation.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/avbp-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-arrivent-biopharma-302901371.html

SOURCE SueWallSt.com